336 related articles for article (PubMed ID: 26967456)
1. Heterogeneity of KRAS Mutations in Pancreatic Ductal Adenocarcinoma.
Hashimoto D; Arima K; Yokoyama N; Chikamoto A; Taki K; Inoue R; Kaida T; Higashi T; Nitta H; Ohmuraya M; Hirota M; Beppu T; Baba H
Pancreas; 2016 Sep; 45(8):1111-4. PubMed ID: 26967456
[TBL] [Abstract][Full Text] [Related]
2. Characterization of KRAS Mutation in Acinar and Langerhans Islet Cells of Patients With Pancreatic Ductal Adenocarcinoma.
Wang Z; Zhang C; Nagee K; Mohammadi A; Monteiro C
Pancreas; 2016 Mar; 45(3):337-41. PubMed ID: 26474433
[TBL] [Abstract][Full Text] [Related]
3. Intratumor Heterogeneity of KRAS Mutation Status in Pancreatic Ductal Adenocarcinoma Is Associated With Smaller Lesions.
Nagawkar SS; Abu-Funni S; Simon E; Bick T; Prinz E; Sabo E; Ben-Izhak O; Hershkovitz D
Pancreas; 2016 Jul; 45(6):876-81. PubMed ID: 26646269
[TBL] [Abstract][Full Text] [Related]
4. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
[TBL] [Abstract][Full Text] [Related]
5. FNA smears of pancreatic ductal adenocarcinoma are superior to formalin-fixed paraffin-embedded tissue as a source of DNA: Comparison of targeted KRAS amplification and genotyping in matched preresection and postresection samples.
Hartley CP; Mahajan AM; Selvaggi SM; Rehrauer WM
Cancer Cytopathol; 2017 Nov; 125(11):838-847. PubMed ID: 29024530
[TBL] [Abstract][Full Text] [Related]
6. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
[TBL] [Abstract][Full Text] [Related]
7. Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma.
Choi MH; Mejlænder-Andersen E; Manueldas S; El Jellas K; Steine SJ; Tjensvoll K; Sætran HA; Knappskog S; Hoem D; Nordgård O; Hovland R; Molven A
BMC Cancer; 2019 Jan; 19(1):11. PubMed ID: 30611220
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
Baldus SE; Schaefer KL; Engers R; Hartleb D; Stoecklein NH; Gabbert HE
Clin Cancer Res; 2010 Feb; 16(3):790-9. PubMed ID: 20103678
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral heterogeneity of KRAS mutation is rare in non-small-cell lung cancer.
Alsdorf WH; Clauditz TS; Hoenig T; Quaas A; Sirma H; Koenig AM; Izbicki J; Sauter G; Marx AH; Grob TJ
Exp Mol Pathol; 2013 Feb; 94(1):155-9. PubMed ID: 23022742
[TBL] [Abstract][Full Text] [Related]
10. Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma.
Huang J; Löhr JM; Nilsson M; Segersvärd R; Matsson H; Verbeke C; Heuchel R; Kere J; Iafrate AJ; Zheng Z; Ye W
Clin Chem; 2015 Nov; 61(11):1408-16. PubMed ID: 26378065
[TBL] [Abstract][Full Text] [Related]
11. Detection of KRAS gene mutations in endoscopic ultrasound-guided fine-needle aspiration biopsy for improving pancreatic cancer diagnosis.
Wang X; Gao J; Ren Y; Gu J; Du Y; Chen J; Jin Z; Zhan X; Li Z; Huang H; Lv S; Gong Y
Am J Gastroenterol; 2011 Dec; 106(12):2104-11. PubMed ID: 21876563
[TBL] [Abstract][Full Text] [Related]
12.
Shiroma N; Arihiro K; Oda M; Orita M
J Clin Pathol; 2018 Oct; 71(10):865-873. PubMed ID: 29695486
[TBL] [Abstract][Full Text] [Related]
13. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
[TBL] [Abstract][Full Text] [Related]
14. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
[TBL] [Abstract][Full Text] [Related]
15. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
16. Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.
Baechmann S; Ormanns S; Haas M; Kruger S; Remold A; Modest DP; Kirchner T; Jung A; Werner J; Heinemann V; Boeck S
BMC Cancer; 2017 May; 17(1):374. PubMed ID: 28549417
[TBL] [Abstract][Full Text] [Related]
17. Concentrations of trace elements and KRAS mutations in pancreatic ductal adenocarcinoma.
Gómez-Tomás Á; Pumarega J; Alguacil J; Amaral AFS; Malats N; Pallarès N; Gasull M; Porta M;
Environ Mol Mutagen; 2019 Oct; 60(8):693-703. PubMed ID: 31066938
[TBL] [Abstract][Full Text] [Related]
18. Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes.
Immervoll H; Hoem D; Kugarajh K; Steine SJ; Molven A
Virchows Arch; 2006 Jun; 448(6):788-96. PubMed ID: 16598499
[TBL] [Abstract][Full Text] [Related]
19. KRAS and PIK3CA mutation frequencies in patient-derived xenograft models of pancreatic and colorectal cancer are reflective of patient tumors and stable across passages.
Tignanelli CJ; Herrera Loeza SG; Yeh JJ
Am Surg; 2014 Sep; 80(9):873-7. PubMed ID: 25197873
[TBL] [Abstract][Full Text] [Related]
20. KRAS mutation analysis of washing fluid from endoscopic ultrasound-guided fine needle aspiration improves cytologic diagnosis of pancreatic ductal adenocarcinoma.
Park JK; Lee YJ; Lee JK; Lee KT; Choi YL; Lee KH
Oncotarget; 2017 Jan; 8(2):3519-3527. PubMed ID: 27974679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]